FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BOGER JOSHUA S					<u>VERTEX PHARMACEUTICALS INC /</u>									Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle)					MA [VRTX]									X		give title	Other (speci		·	
C/O VERTEX PHARMACEUTICALS INCORPORATED					3. Date of Earliest Transaction (Month/Day/Year) 09/09/2003										Chairman & CEO					
130 WAVERLY STREET					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
(Street)	(Street) CAMBRIDGE MA 02139													X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)																	
		Tal	ble I - No	n-Deri	vativ	e Se	curi	ties A	cquired	, Dis	posed o	f, or Ber	nefici	ially	Owned					
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			r and 5)		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of ndirect Beneficial Ownership			
							Code	v	Amount	(A) or (D)		e	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)			
Common	Stock			09/0	9/200)3			М		20,000) A	\$7	7.88	880	,977		D		
Common	Stock			09/0	9/200)3			S ⁽¹⁾		20,000) D	\$1	4.46	860	,977		D		
Common Stock														217	′,022		I S	9,522 shares 401(k); 207,500 shares in rust ⁽²⁾		
			Table II -								osed of, convertil				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		n of E		Expiratio	5. Date Exercisal Expiration Date Month/Day/Year		of Securities		[8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	e s dly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Cod	Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amou or Numl of Share	ber						
Stock Option	\$7.88	09/09/2003			M			20,000	03/31/199	4 ⁽³⁾	11/30/2003	Common Stock	20,0	000	\$0	1,763,2	223	D		

Explanation of Responses:

- 1. Transaction made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.
- 2. Shares held in trust for Dr. Boger's children. Dr. Boger disclaims beneficial ownership of such shares.
- 3. Right to buy under 1991 Stock and Option Plan, vesting in 20 equal quarterly installments from 12/01/1993.

Remarks:

Valerie L. Andrews, Attorney-

09/10/2003

In-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.